Lung volume reduction therapy using crosslinked non-natural polymers
View Patent ↗One aspect of the invention relates to a hydrogel comprising a non-natural polymer comprising a plurality of pendant nucleophilic groups and a crosslinker comprising at least two pendant electrophilic groups. Another aspect of the invention relates to a hydrogel comprising a non-natural polymer comprising a plurality of pendant electrophilic groups and a crosslinker comprising at least two pendant nucleophilic groups. Yet another aspect of the invention relates to a method for reducing lung volume in a patient comprising the step of administering a hydrogel composition as described herein. Further, hydrogels of the invention may be used to achieve pleurodesis, seal brochopleural fistulas, seal an air leak in a lung, achieve hemostasis, tissue sealing (e.g., blood vessels, internal organs), or any combination thereof. In certain embodiments, the compositions and methods described herein are intended for use in the treatment of patients with emphysema.
1. A method for reducing lung volume in a patient, comprising the step of administering to a patient in need thereof a therapeutically effective amount of a hydrogel, wherein said hydrogel is prepared from a first non-natural polymer and a first cross-linker; said first non-natural polymer comprises a plurality of pendant first nucleophilic groups; said first cross-linker comprises at least two pendant first electrophilic groups; and
said first non-natural polymer consists essentially of a plurality of subunits independently selected from the group consisting of
wherein independently for each occurrence
X is —(C(R) 2 ) n —, —(CH 2 OCH 2 ) n CH 2 —, —(CH 2 ) n -(cycloalkyl)-(CH 2 ) n —, or —(CH 2 ) n -(aryl)-(CH 2 ) n —;
R is H or lower alkyl;
Y is —NHR′, —OH or —SH;
R′ is hydrogen, NH 2 , aliphatic, aromatic, heterocyclic, cycloaliphatic or a saturated heterocyclic moiety;
n is 1-20; and
about 60 mol % to about 99 mol % of the subunits are
2. The method of claim 1 , wherein said hydrogel is administered using a bronchoscope.
3. The method of claim 1 , wherein said hydrogel is administered using a catheter.
4. The method of claim 1 , wherein X is —(C(R) 2 ) n —; and R is H.
5. The method of claim 1 , wherein Y is NHR′; and R′ is H.
6. The method of claim 1 , wherein X is —(C(R) 2 ) n —; R is H; Y is NHR′; and R′ is H.
7. The method of claim 1 , wherein said first electrophilic groups are selected from the group consisting of aziridines, episulfides, cyclic sulfates, carbonates, imines, esters, lactones, halides, epoxides, hydroxysuccinimidyl esters, maleimides, iodoacetamides, phosphates, sulfates, sulfonates, ketones and aldehydes.
8. The method of claim 1 , wherein said first cross-linker is a polyaldehyde.
9. The method of claim 1 , wherein said first cross-linker is a dialdehyde.
10. The method of claim 1 , wherein said first cross-linker is glutaraldehyde.
11. The method of claim 1 , wherein said first cross-linker is represented by the following formula:
wherein independently for each occurrence
n is 0-12;
m is 0-12; and
Y is a di-radical of an aliphatic, cycloaliphatic, aromatic, heterocycloaliphatic or heterocyclic moiety.
12. The method of claim 1 , wherein said first cross-linker is represented by the following formula:
wherein independently for each occurrence
n is 0-12;
m is 0-12; and
R 4 and R 5 are each independently hydrogen, aliphatic, cycloaliphatic, aromatic, heterocycloaliphatic or heterocyclic moiety.
13. A method for reducing lung volume in a patient, comprising the step of administering to a patient in need thereof a therapeutically effective amount of a hydrogel, wherein said hydrogel is prepared from a second non-natural polymer and a second cross-linker; said second non-natural polymer comprises a plurality of second electrophilic groups; said second cross-linker comprises at least two pendant second nucleophilic groups; and
said second non-natural polymer consists essentially of a plurality of subunits independently selected from the group consisting of
wherein independently for each occurrence
X is —(C(R) 2 ) n —, —(CH 2 OCH 2 ) n CH 2 —, —(CH 2 ) n -(cycloalkyl)-(CH 2 ) n —, or —(CH 2 ) n -(aryl)-(CH 2 ) n —;
R is H or lower alkyl;
Z is —C(O)R″, —C(S)R″, halide, —C(NR″)R″, —OP(O)(OR″) 2 , —OP(O)(OR″)(R″), —OS(O) 2 (OR″), or —OS(O) 2 R″;
R″ is hydrogen, aliphatic, aromatic or heterocyclic;
n is independently for each occurrence 1-20; and
about 60 mol % to about 99 mol % of the subunits are
14. The method of claim 13 , wherein X is —(C(R) 2 ) n — and R is H.
15. The method of claim 13 , wherein Z is an aldehyde.
16. The method of claim 13 , wherein X is —(C(R) 2 ) n —; R is H; and Z is an aldehyde.
17. The method of claim 13 , wherein said second nucleophilic groups are selected from the group consisting of alcohols, amines, hydrazines, cyanides, or thiols.
18. The method of claim 13 , wherein said second cross-linker is a polyamine, polyalcohol or polythiol.
19. The method of claim 13 , wherein said second cross-linker is a diamine, dialcohol or dithiol.
20. The method of claim 13 , wherein said second cross-linker is represented by the following formula:
wherein independently for each occurrence
n is 0-12;
m is 0-12;
R 6 is selected from the group consisting of alcohols, amines, hydrazines, cyanides and thiols; and
Y is a di-radical of an aliphatic, cycloaliphatic, aromatic, heterocycloaliphatic or heterocyclic moiety.
21. The method of claim 13 , wherein said second cross-linker is represented by the following formula:
wherein independently for each occurrence
n is 0-12;
m is 0-12;
R 4 and R 5 are each independently hydrogen, aliphatic, cycloaliphatic, aromatic, heterocycloaliphatic or heterocyclic moiety; and
R 6 is selected from the group consisting of alcohols, amines, hydrazines, cyanides and thiols.
22. The method of claim 1 , wherein said hydrogel is introduced into a target region of the patient's lung.
23. The method of claim 1 , wherein said hydrogel is administered as a foam.
24. The method of claim 1 , wherein X is —(C(R) 2 ) n —; R is H; Y is NHR′; R′ is H; and said first cross-linker is a dialdehyde.
25. The method of claim 1 , wherein X is —(C(R) 2 ) n —; R is H; Y is NHR′; R′ is H; and said first cross-linker is glutaraldehyde.
26. The method of claim 1 , wherein X is —(C(R) 2 ) n —; R is H; Y is NHR′; R′ is H; said first cross-linker is glutaraldehyde; and said hydrogel is administered as a foam.
27. The method of claim 13 , wherein said hydrogel is introduced into a target region of the patient's lung.
28. The method of claim 13 , wherein said hydrogel is administered as a foam.
29. The method of claim 13 , wherein said hydrogel is administered using a bronchoscope.
30. The method of claim 13 , wherein said hydrogel is administered using a catheter.
31. The method of claim 13 , wherein X is —(C(R) 2 ) n —; R is H; Z is an aldehyde; and said second cross-linker is a polyamine, polyalcohol or polythiol.
32. The method of claim 13 , wherein X is —(C(R) 2 ) n —; R is H; Z is an aldehyde; and said second cross-linker is a diamine, dialcohol or dithiol.
33. The method of claim 13 , wherein X is —(C(R) 2 ) n —; R is H; Z is an aldehyde; said second cross-linker is a diamine, dialcohol or dithiol; and said hydrogel is administered as a foam.